The biopharmaceutical industry’s commercial model has been an important part of each company’s success, but the current capabilities and strategies are unlikely to suffice for future …

Artificial intelligence-enabled technologies are transforming the different parts of the biopharma industry value chain, creating new business opportunities. Explore Deloitte's collection of …

May 6, 2021 · Consumers may appreciate pharma companies’ efforts to speed up the process of bringing COVID-19 vaccines to market. How might biopharma continue to innovate while …

Biopharma and medtech companies are investing in fully digitizing and integrating information technology (IT) and operational technology (OT) capabilities in manufacturing.2 As smart …

Inorganic growth activity in life sciences— have we reached the bottom? Our previous report outlined a steep decline in life sciences deal-making in the first half of 2022 from record levels …

In 2024, US manufacturing experienced continued investment even as higher interest rates and a challenging business environment have created obstacles to near-term industry growth. …

Apr 10, 2024 · バイオ・創薬スタートアップは新規モダリティの創出の原動力であり、ひとたび新規モダリティが上市されると、それらは大きな市場を形成し、同時に業界構造についても …

A potential use of digital twins among biopharma companies is the simulation of clinical trials to include budgets, patient selection, and probability of success.9 Digital twins can form part of a …

2024年10月から11月にかけて実施された2025年度版グローバル自動車消費者調査では、次の4つの主要なトレンド取り上げる。 ほとんどの市場でバッテリー式電気自動車（BEV）への関 …

More than 3/4 of biopharma companies agree that their organizations need new leaders to succeed in the digital age. Many companies are recruiting outside of life sciences for digital …